Dear Subscriber,

Jacob Fleming Conferences will bring together the experts to benchmark the best practices in

Pharma & Biotech IP & Litigation
(21st & 22nd February 2008, Brussels)

 

Protecting IP is a crucial issue in the Pharma industry. Successful pharma & biotech companies already understand that the IP and patenting practices are also essential in facilitating enhanced market exclusivity and revenue returns.

Register and understand how the various patent offices throughout the world examine patent applications!

Get practical information about...

• the differences of the patent & legal issues in innovative and generic companies by Martin Voet, Senior VP Chief IP Councel, Allergan, USA
• how to adopt the recent developments in US Pharmaceutical Patent Litigation policies by Mark Rachlin, Senior Patent Counsel for Litigation, GSK, USA
• how to strengthen IP protection worldwide, by UCB, China, Sanofi Aventis, Portugal, Matrix Laboratories, India, etc. 
• the impacts of the EU wide litigation by Jay Deshmukh, SVP Global IP, Ranbaxy
• the strategies to adapt the directives and regulation from EPO, the EU, the US, etc. regulators by Ipsen, France, Johnson & Johnson, Belgium,European Patent Office, Germany

and many more...

 Click here to recive the full brochure!

If you think this event would be of interest to your business partners or colleagues, please feel free to share it with them.

I'm looking forward to welcome you in Brussels.

Best regards,

Kriszta